The publication reveals that FABP7, an intracellular protein involved in the uptake, transportation, metabolism, and storage of fatty acids, is upregulated in several cancers including breast, brain, and kidney cancers and is generally associated with a poor patient prognosis. Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies. Moreover, inhibition of FABP7 improved host survival rates, particularly in brain cancers, indicating its role as a novel target in cancer.
“Artelo is dedicated to furthering research on FABP inhibition including selective- and pan-FABP inhibition, with the aim of providing new therapeutic options for patients battling cancer and other serious conditions,” said Professor Saoirse Elizabeth O’Sullivan, Vice President of Translational Sciences at
Artelo is currently evaluating multiple compounds for their therapeutic potential from the Company’s extensive FABP inhibitor library. The most advanced of these is ART26.12, a novel, potent and selective inhibitor of FABP5. In preclinical studies, ART26.12 demonstrated positive results in cancer, cancer bone pain, and painful neuropathies such as chemotherapy-induced peripheral neuropathy (CIPN). Artelo plans to file an investigational new drug (IND) application with the
For more information about
About ART26.12
ART26.12, Artelo’s lead Fatty Acid Binding Protein (FABP) inhibitor, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with an initial clinical study planned for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. Beyond ART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs have shown therapeutic promise for the treatment of certain cancers, cancer bone pain, neuropathic and nociceptive pain, dermatological and anxiety disorders.
About
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, market opportunity, competitive position, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the
Investor Relations Contact:
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
Source:
2024 GlobeNewswire, Inc., source